Health FP7. UMB 27. mai 2011 Seniorrådgiver Berit Nygaard

Transkript

1 Health FP7 UMB 27. mai 2011 Seniorrådgiver Berit Nygaard

2 FP7 HEALTH - hovedområdene i det tematiske programmet Pillar 1 Pillar 2 Pillar 3 Bioteknologi, generiske metoder og medisinske teknologier Translasjons- forskning de store folkesykdommene Forebyggende helse og helsetjenesteforskning The Innovative Medicines Initiative Pillar 4 Implementering av FP7&EU politikk: fremtidige behov, formidling P t d l d f k i dt f k i Programmet adresserer grunnleggende forskning, anvendt forskning, translasjonsforskning samt kliniske studier

3 Health 6. utlysning Prioriteringer Aktiv og sunn aldring SMB-relevant forskning (15-50% i mange prosjekter) Medisinske teknologier Sjeldne sykdommer Forskerdrevne kliniske studier Formidling og resultatspredning

4 Health 6. utlysning Strategiske valg Konsentrasjon av midlene mange underområder lukket 37 temaer/problemstillinger («topics») Ca halvparten krav om/fordel med SMB-inklusjon Budsjett på ca 620 mill Euro To-trinns behandling av alle søknader

5 Health 6. utlysning Annen viktig informasjon Internasjonalt samarbeid (med tredje land) Sammen med programmene KBBE, ICT og SHH bidrar HEALTH med forskning for å realisere European Innovation Partnership (EIP) «healthy aging» Viktig å adressere potensielle etiske utfordringer i prosjektet Redusere bruk av forsøksdyr i forskningen Tilstrebe kjønnsbalanse i forskergruppene

6 Utlysningsteksten (obs utkast) (Orientation Paper 2012) offentliggjort medio mai CORDIS: Publisering av utlysningen planlagt til 20. juli 2011 Tentative søknadsfrister (stage 1) 27. september (3 prosjekter) og 4. oktober (resten

7 Health 6. utlysning Underområder som er lukket High-throughput research Pilar 1 Suitability, safety, efficacy of therapies Brain and brain-related diseases Pilar 2 Anti-microbial drug resistance Potentially new and re-emerging epidemics Neglected infectious diseases Cancer Cardiovascular diseases Translating the results of clinical research Pilar 3 outcome into clinical practice Health promotion and prevention

8 Health 6. utlysning Antall partnere (utover min. 3) i konsortiet Sammensetning av konsortiet* Prosjektets varighet* bestemmes av søker fleksibelt * Det kan være andre anbefalinger for Det kan være andre anbefalinger for enkelte tema

9 1. Biotechnology, generic tools and medical technologies for human health (155 mill. ) Detection, ti diagnosis i and monitoring i Development of technologies with a view to patient group stratification for personalised medicine applications Innovative therapeutic approaches and interventions ti Innovative approaches to solid organ transplantation Medical technology for transplantation and bioartificial organs Innovative strategies t for translation ti of stem cell based therapies in regenerative medicine Targeted nucleic acid delivery as innovative therapeutic or prophylactic approach

10 2. Translating research for human health h (375 mill. ) Integrating g biological data and processes: Large-scale data gathering Support for international rare disease research Clinical utility of omics for better diagnosis of rare diseases Databases, biobanksb and clinical i l bioinformatics hub for rare diseases Validation of -omics based biomarkers for diseases affecting the elderly Statistical methods for collection and analysis of -omics data

11 2. Translating research for human health (375 mill. ) Systems biology/medicine Systems medicine: SME-driven research applying systems biology approaches to adress medical and clinical needs Applying systems biology approaches for understanding complex human diseases and their co-morbidity Preparing for the future research and innovation activities in systems medicine

12 2. Translating research for human health h (375 mill. ) Research on the brain and related diseases, human development and ageing Human development and ageing Integrative systems biology and comparative genomics for studying human ageing and/or most common age-related diseases Investigator-driven clinical trials for optimisation of management of elderly patients with multiple diseases

13 2. Translating research for human health h (375 mill. ) Translational research in major infectious diseases: to confront threats to public health Cross cutting Diagnostics for infectious diseases ERA-NET on infectious diseases HIV/AIDS, malaria and tuberculosis Co-infection of HIV/AIDS, malaria, tuberculosis and/or hepatitis epatts Co-morbidity between infectious and noncommunicable diseases Preventioen and treatment t t for HIV/AIDS, malaria, tuberculosis Low-cost interventions for disease control in resource poor settings

14 2. Translating research for human health h (375 mill. ) Translational research in other major diseases Diabetes and obesity Innovative approach to manage diabetes Investigator-driven clinical trials for type 1 diabetes research Rare diseases Preclinical and/or clinical development of substances with a clear potential as orphan drugs Observational trials in rare diseases Bets practice and knowledge sharing in the clinical management of rare diseases

15 2. Translating research for human health h (375 mill. ) Translational research in other major diseases Other chronic diseases Technological approaches to combating sensory impairments Biomarkers and diagnostics for chronic g inflammatory diseases of the joints and/or digestive system

16 3. Optimising i i the delivery of healthcare h to European citizens (50 mill. ) Quality, efficiency and solidarity of healthcare systems including transnational health systems Improving the organisation of health service delivery New methodologies for health h technology assessment Social innovation for ageing research International public health and health systems Research on health systems and services in lowand middle-income countries

17 4. Actions across the Health lh theme (20 mill. ) Coordination and Support Actions Network to encourage knowledge transfer activity in FP-funded health research Training actions linked to intellectual property rights management and knowledge transfer Support for Presidency events: Organisation of supporting actions and events related to the Presidency of the European Union Communicating the benefits of European research to the general public Prepare the future for health research and innovation

18 FP7 Health Resultater per Sammenlikning nordiske land Ant. søknader Ant. prosjekter Suksessrate (%) DK FI NO SE

19 2012-utlysninger i andre tematiske ti programmer med relevans for helse KBBE Food, Agriculture, Fisheries and Biotechnology Food, health, diet-related diseases, consumer behaviour ICT - Information and Communications Technologies Virtual Physiological Human NMP Nanosciences, Nanotechnologies, Materials and new Production Technologies (NMP) Nanotech. systems for diagnosis & treatment, nanomedicine, toxicity of nanoparticles SHH Socioeconomic Sciences and Humanities Making longevity an asset for economic and social development, European childhood and youth survey

20 FP7 Health utlysning (siste) juli 2012 tentativt: Hjernen og hjernesykdommer Trolig «Year of the Brain» Kreft Hjerte-karsykdommer Vaksiner og medisiner - parasittsykdommer Comparative Effectivness Studies Helseundersøkelser helsefremme/forebygging Stor andel prosjekter med SMB-deltakelse

21 FP7 Health - Hvordan finne partnere? database for partnersøk Potensielle prosjektpartnere t åpen dag 10. juni i Brüssel eu/research/health/events en html Prosjektdatabase: Åpen informasjonsdag i Brüssel 9. juni

22 Utlysning pilot JPI Neurodegenerative Disease (Alzheimer) Transnational call for optimisation of biomarkers and harmonisation of their use Søknadsfrist 5. september 2011 Kontaktperson NFR: Karianne Solaas; NevroNor-koordinator

23 FP7 Health Kontaktpersoner NCP Health: Berit Nygaard, , Økonomi og finans: Yngve Foss, , IMI: Hans M. Borchgrevink, , Research infrastructure: Solveig Flock, , ERC: Per Ivar Høvring, SMB: Vebjørn Walderhaug, ,

24 Takk for oppmerksomheten!

25 Muligheter i andre tematiske ti program KBBE: complementary to Theme Health KBBE : 01: Role of health-related symbols and claims in consumer behaviour KBBE : Beneficial effects of bioactive compounds in humans KBBE : : Study on the needs for food and health research infrastructures KBBE : Impact of lifestyle l on well-being and diet-related disease K KBBE : Role of health-related symbols and claims in consumer behaviour

26 Muligheter i andre tematiske program Social Sciences and Humanities SSH: complementary to Theme Health ERA-net Coordinating research economic agendas Making longevity an asset for economic and social development A European childhood and youth survey Forward looking tools and methods for answering Forward looking tools and methods for answering major societal challenges

27 NMP: complementary to Theme Health NMP : Development and phase-i clinical trials of novel therapeutic nanotechnology-enabled systems for the diagnosis and treatment of atherosclerosis NMP : ERA-NET on nanomedicine NMP : Systematic investigations of the mechanisms and effects of engineered nanomaterial interactions with living systems and/or the environment NMP : Modelling toxicity behaviour of engineered nanoparticles NMP Bi t i l f i d f NMP : Biomaterials for improved performance of medical implants

28 ICT: complementary to Theme Health ICT Virtual Physiological Human (call 9) a) Patient-specific predictive computer-based models and simulation b) Development of ICT tools, services and infrastructure to obtain more elaborate and reusable multi-scale model d) Early demonstrators and proof of concept of digital representations of health status All other areas of challenge 5: ICT for Health, Ageing Well, Inclusion and Governance are closed in 2012

29 Health - prosjekttyper (funding schemes) ) 2012 Funding scheme Ceiling for EU contribution i Number of topics % budget Large-scale 12m 4 ~ 16.5% integrating project (CP-IP) Small or medium 3m / 6m 24 ~ 78% scale focused project (CP-FP) Coordinating or supporting action (CSA) various 9 ~ 2.5% Other actions* various ~ 2% Total %